About
PolTREG develops engineered regulatory T cell (Treg) therapies aimed at treating autoimmune diseases including Type-1 Diabetes, Multiple Sclerosis, and ALS. The company has a leading pipeline with clinical assets targeting disease-modifying treatments using CAR-Tregs.
Explore PolTREG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.